# Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

> **NCT02653482** · PHASE4 · COMPLETED · sponsor: **Saint Luke's Health System** · enrollment: 263 (actual)

## Conditions studied

- Chronic Heart Failure With Reduced Systolic Function

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin matching placebo

## Key facts

- **NCT ID:** NCT02653482
- **Lead sponsor:** Saint Luke's Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-03
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2022-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02653482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02653482, "Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT02653482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*